Santen Pharmaceutical Co., Ltd.

R-Tech Ueno, Ltd.

Asahi Glass Company, Limited

Hiroyuki Asada

Akio Kimura

Mitsuaki Kuwano

Atsutoshi Ota

Asuka Kamimura

Kenji Morishima

Yusuke Momokawa

Kenichi Endo

Masayuki Umeda

Takehiro Kado

Tomoyuki Okamoto

An eye drop composition in which the degradation of isopropyl unoprostone in an eye drop is prevented by adding trometamol to the eye drop containing isopropyl unoprostone.

Eye drop composition containing isopropyl unoprostone

A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic.

Clear ophthalmic solution comprising latanoprost as active ingredient

An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least one means selected from the following 1) to 3); 1) adding a surfactant, 2) using benzalkonium chloride represented by the formula of [CHCHN(CH)R]Cl (wherein R is alkyl having 12 carbon atoms) as the preservative and 3) adding a nonionic tonicity agent as a tonicity agent.

Transparent eye drops containing latanoprost

The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.

Method for prevention of degradation of thermally unstable medicament

An object of the present invention is to provide an aqueous solution of lactoferrin which can be preserved for a long period of time. The aqueous preparation according to the present invention is an aqueous preparation which is characterized by containing a polyvalent inorganic or organic acid or a salt thereof whereby stability of lactoferrin is improved and is an aqueous preparation in which concentration of the polyvalent inorganic or organic acid or a salt thereof is 0.005% (w/v) or more. In the case of ophthalmic solutions, for example, the polyvalent inorganic or organic acid or a salt thereof is preferably 0.01-3.0% (w/v), particularly preferably 0.1-1.0% (w/v).

Growing community of inventors

Osaka, Japan

Hiroyuki Asada